Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: A single center clinical experience with long-term follow-up data and a brief overview of the literature

International Journal of Dermatology

Volumn 52, Issue 11, 2013, Pages 1308-1318

  Quaglino, Pietro ^a   Knobler, Robert ^b   Fierro, Maria T ^a   Savoia, Paola ^a   Marra, Elena ^a   Fava, Paolo ^a   Bernengo, Maria G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEXAROTENE; CD3 ANTIGEN; CD8 ANTIGEN; CHLORAMBUCIL; DOXORUBICIN; FLUDARABINE; GEMCITABINE; INTERFERON; METHOTREXATE; METHOXSALEN; RETINOID;

ADULT; AGED; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSONAL EXPERIENCE; PUVA; REVIEW; ULTRAVIOLET A RADIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD8; CD4-CD8 RATIO; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PHOTOPHERESIS; PRACTICE GUIDELINES AS TOPIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS;

EID: 84886746303     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12121     Document Type: Review

References (81)

1. Lutzner M, Edelson R, Schein P, et al. Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975; 83: 534-552.
2. Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-5073.
3. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143: 854-859.
4. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.
5. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
6. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
7. Hwang ST, Janik JE, Jaffe ES, et al. Mycosis fungoides and Sézary syndrome. Lancet 2008; 371: 945-957.
8. Pimpinelli N, Olsen EA, Santucci M, et al. International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-1063.
9. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-4739.
10. Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways and long-term hazard risk trends of disease progression in classic Mycosis fungoides: a multicenter retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 2012; 118: 5830-5839.
11. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-1030.
12. Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011; 64: 352-404.
13. Bernengo MG, Quaglino P, Novelli M, et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol 1998; 9: 857-863.
14. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297-303.
15. Knobler R, Barr ML, Couriel DR, et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol 2009; 61: 652-665.
16. Ward DM. Extracorporeal photopheresis: how, when, and why. J Clin Apher 2011; 26: 276-285.
17. Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis - results of a crossover randomized study. Biol Blood Marrow Transplant 2011; 17: 1775-1782.
18. Marques MB, Schwartz J. Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apher 2011; 26: 146-151.
19. Scarisbrick JJ, Taylor P, Holtick U, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008; 158: 659-678.
20. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010; 8: 288-334.
21. Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 21: 177-180.
22. Bladon J, Taylor PC. Extracorporeal photopheresis: a focus on apoptosis and cytokines. J Dermatol Sci 2006; 43: 85-94.
23. Miracco C, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study. Br J Dermatol 1997; 137: 549-557.
24. Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999; 107: 707-711.
25. Osella-Abate S, Zaccagna A, Savoia P, et al. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy. J Am Acad Dermatol 2001; 44: 40-47.
26. Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001; 91: 438-447.
27. Mahnke K, Johnson TS, Ring S, et al. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 2007; 46: 159-167.
28. Long SA, Buckner JH. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 2011; 187: 2061-2066.
29. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004; 114: 1198-1208.
30. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
31. Schmitt S, Johnson TS, Karakhanova S, et al. Extracorporeal photophoresis augments function of CD4+CD25+FoxP3+ regulatory T cells by triggering adenosine production. Transplantation 2009; 88: 411-416.
32. Xia CQ, Campbell KA, Clare-Salzler MJ. Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells. Curr Opin Organ Transplant 2009; 14: 338-343.
33. Szodoray P, Papp G, Nakken B, et al. The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation. Autoimmun Rev 2010; 9: 459-464.
34. Rao V, Saunes M, Jørstad S, et al. Cutaneous T cell lymphoma and graft-versus-host disease: a comparison of in vivo effects of extracorporeal photochemotherapy on Foxp3+ regulatory T cells. Clin Immunol 2009; 133: 303-313.
35. Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005; 174: 5968-5976.
36. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005; 79: 846-850.
37. Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci 2001; 941: 1-11.
38. Klemke CD, Fritzsching B, Franz B, et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-1129.
39. Tiemessen MM, Mitchell TJ, Hendry L, et al. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 2217-2223.
40. Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007; 21: 2512-2518.
41. Shofner JD, Vasquez JG, Berger CL, et al. Improved generation of anti-tumor immunity by antigen dose limitation. J Immune Based Ther Vaccines 2007; 5: 2-13.
42. Quaglino P, Comessatti A, Ponti R, et al. Reciprocal modulation of circulating CD4 + CD25+ bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versus-host-disease patients. Int J Immunopathol Pharmacol 2009; 22: 353-362.
43. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci 2003; 28: 81-89.
44. Zic JA. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status. Curr Opin Oncol 2012; 24: S1-S10.
45. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337-346.
46. Heald PW, Perez MI, Christensen I, et al. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. Yale J Biol Med 1989; 62: 629-638.
47. Zic J, Arzubiaga C, Salhany KE, et al. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1992; 27: 729-736.
48. Koh H, Davis B, Meola T, et al. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T-cell lymphoma. J Invest Dermatol 1994; 102: 567.
49. Prinz B, Behrens W, Holzle E, et al. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma-the Dusseldorf and Munich experience. Arch Dermatol Res 1995; 287: 621-626.
50. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-957.
51. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573-579.
52. Zic JA, Stricklin GP, Greer JP, et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-945.
53. Russell-Jones R, Fraser-Andrews E, Spittle M, et al. Extracorporeal photopheresis in Sézary syndrome. Lancet 1997; 350: 886.
54. Konstantinow A, Balda B. Treatment of cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Eur Acad Dermatol Venereol 1997; 9: 111-117.
55. Vonderheid EC, Zhang Q, Lessin SR, et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 207-220.
56. Zouboulis CC, Schmuth M, Doepfmer S, et al. Extracorporeal photopheresis of cutaneous T-cell lymphoma is associated with reduction of peripheral CD4+ T lymphocytes. Dermatology 1998; 196: 305-308.
57. Jiang SB, Dietz SB, Kim M, et al. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: a 9.7-year experience. Photodermatol Photoimmunol Photomed 1999; 15: 161-165.
58. Bisaccia E, Gonzalez J, Palangio M, et al. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution. J Am Acad Dermatol 2000; 43: 263-271.
59. Crovetti G, Carabelli A, Berti E, et al. Photopheresis in cutaneous T-cell lymphoma: five-year experience. Int J Artif Organs 2000; 23: 55-62.
60. Wollina U, Looks A, Meyer J, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001; 44: 253-260.
61. Bouwhuis SA, el-Azhary RA, McEvoy MT, et al. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine. Int J Dermatol 2002; 41: 352-356.
62. Knobler E, Warmuth I, Cocco C, et al. Extracorporeal photochemotherapy - the Columbia Presbyterian experience. Photodermatol Photoimmunol Photomed 2002; 18: 232-237.
63. Stevens SR, Baron ED, Masten S, et al. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis. Arch Dermatol 2002; 138: 1347-1350.
64. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054-1060.
65. Quaglino P, Fierro MT, Rossotto GL, et al. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol 2004; 150: 327-336.
66. de Misa RF, Harto A, Azana JM, et al. Photopheresis does not improve survival in Sézary syndrome patients with bone marrow involvement. J Am Acad Dermatol 2005; 53: 171-172.
67. Rao V, Ryggen K, Aarhaug M, et al. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable? J Eur Acad Dermatol Venereol 2006; 20: 1100-1107.
68. Arulogun S, Prince HM, Gambell P, et al. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. J Am Acad Dermatol 2008; 59: 589-595.
69. Booken N, Weiss C, Utikal J, et al. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome. J Dtsch Dermatol Ges 2010; 8: 428-438.
70. Talpur R, Demierre MF, Geskin L, et al. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk 2011; 11: 219-227.
71. McGirt LY, Thoburn C, Hess A, et al. Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome. Photodermatol Photoimmunol Photomed 2010; 26: 182-191.
72. Raphael BA, Shin DB, Suchin KR, et al. High clinical response rate of Sézary syndrome to immunomodulatory therapies: prognostic markers of response. Arch Dermatol 2011; 147: 1410-1415.
73. Siakantaris MP, Tsirigotis P, Stavroyianni N, et al. Management of cutaneous T-cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience. Transfus Apher Sci 2012; 46: 189-193.
74. Russell-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000; 142: 16-21.
75. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-433.
76. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-100.
77. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+CD26- subset in the identification of circulating Sézary cells. Br J Dermatol 2001; 144: 125-135.
78. Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784-794.
79. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
80. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
81. Olsen EA, Whittaker S, Kim YH, et al. Clinical end-points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29: 2598-2607.